​

Overcoming the limits of standard-of-care therapies

Starton is a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technology so that people with cancer can receive continuous treatment and live better and longer.

“Cancer touches all of us, directly and indirectly.Today, life is often extended for a short period, and for most people withcancer, the quality of life deteriorates significantly. At Starton, we are developing an approach to provide people with cancer longer, high-quality-lives. We are eliminating or minimizing the horrible side effects they experience every day by unlocking the full potential of approved drugs.”

Pedro Lichtinger, Co-Founder, Chairman,& CEO

‍

​